2,212 Shares in Axon Enterprise, Inc $AXON Purchased by Themes Management Co LLC

Themes Management Co LLC acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,212 shares of the biotechnology company’s stock, valued at approximately $1,256,000.

Several other hedge funds have also bought and sold shares of the business. Harbour Investments Inc. boosted its stake in Axon Enterprise by 140.4% during the fourth quarter. Harbour Investments Inc. now owns 856 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 500 shares in the last quarter. Allstate Corp boosted its stake in Axon Enterprise by 105.2% during the fourth quarter. Allstate Corp now owns 5,582 shares of the biotechnology company’s stock worth $3,170,000 after acquiring an additional 2,862 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Axon Enterprise by 5.7% during the fourth quarter. Fisher Asset Management LLC now owns 963 shares of the biotechnology company’s stock worth $547,000 after acquiring an additional 52 shares in the last quarter. Clearstead Advisors LLC boosted its stake in Axon Enterprise by 18.4% during the fourth quarter. Clearstead Advisors LLC now owns 882 shares of the biotechnology company’s stock worth $501,000 after acquiring an additional 137 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Axon Enterprise by 1.3% during the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after acquiring an additional 5,419 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $386.00 on Tuesday. The firm’s 50 day moving average price is $414.25 and its 200-day moving average price is $499.29. The company has a market cap of $31.11 billion, a PE ratio of 155.02, a P/E/G ratio of 7.02 and a beta of 1.44. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business’s revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.47 earnings per share. On average, equities research analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Insider Activity

In other news, CAO Jennifer H. Mak sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the transaction, the chief accounting officer directly owned 12,240 shares of the company’s stock, valued at $7,019,028. The trade was a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,855 shares of company stock valued at $7,109,828 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Royal Bank Of Canada dropped their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Piper Sandler dropped their target price on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. UBS Group dropped their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.